Skip to main content Skip to navigation

[University home]

School of Medicine

Professor Shôn Lewis 

Photograph of Shôn Lewis

Professor of Adult Psychiatry

 

Research

Psychosis and schizophrenia usually start in early adult life and affect more than one in 100 people in the UK. It is a strange and mostly devastating disorder from which 80% will never recover. The first susceptibility genes for psychosis have now been identified and the environmental factors which trigger full psychosis in predisposed individuals increasingly appear to include psychosocial factors.

Shôn’s research has focussed on early psychosis as potentially the most important context in which to clarify mechanisms of progression, and to test new treatments. With Professors Nick Tarrier and Richard Bentall, it was shown for the first time that a specific psychologicial intervention (cognitive therapy), when added to drug treatment, could accelerate recovery and improve clinical outcome. With a focus even earlier in the disorder, with Dr Tony Morrison, it has been shown that intervention for prodromal symptoms can reduce the risk of first episode psychosis in at risk individuals. Earlier still, it has been shown that solitary subclinical symptoms can be picked up in the general population.

Shôn and colleagues have shown for the first time that the internet can be used to identify such individuals and, using functional brain imaging, the location in the cortex for these pre-prodromal symptoms has been established.

In 2004, Shôn, with colleagues Iain Buchan, Carole Goble and others, were awarded a £2.2m strategic grant from the MRC to deploy e-science methods to collect data on people presenting with first episode psychosis to the services included in the UK Mental health Research Network.

 

Biography

Shôn Lewis has been Professor of Adult Psychiatry at The University of Manchester since 1994. He trained clinically at the Maudsley Hospital and began his research career at the Institute of Psychiatry, London, with Robin Murray, on neurodevelopmental factors in schizophrenia.

He was Head of the School of Psychiatry and Behavioural Sciences in Manchester 1998-2002, chair of the Royal College of Psychiatrists’ research committee 1996-2001, council member of the British Association of Psychopharmacology 1999-2002, established the European First Episode Psychosis Network in 1996 and was board member of the International Early Psychosis Association 2000-2005. He was a member of the Wellcome Trust Neurosciences and Mental Health Panel 1998-2001 and has been a member of the Medical Research Council Neurosciences and Mental Health Board and the Cross-board Clinical Trials group since 2005.

He is joint Director of the Stanley Medical Institute International Research Centre (Manchester), R&D Director of Manchester Mental Health and Social Care Trust and Associate Director of the UK Mental Health Research Network.

Shôn's research interests focus on risk factors and interventions in early psychosis. He is chief investigator on the MRC clinical e-science grant in early psychosis (PsyGrid).

He was elected to the Academy of Medical Sciences in 2007.

 

Qualifications

 
Subject Degree Class University Date
Psychology BSc (Intercalated) 1st (Hons) London 1976
  LRCP, MRCS   London 1979
  MBBS   London 1979
  MRCPsych   London 1984
  MD   London 1993
  FRCPsych     1988
  FMedSci     2002

 

Publications

2011

  • Morrison A, French P, Stewart S, Birchwood M, Fowler D, Gumley A, Jones P, Bentall R, Lewis SW, Murray G, Patterson P, Brunet A, Conroy P, Parker S, Reilly J, Byrne R, Davies L, Dunn G. (2011). Early detection and intervention evaluation for people at high-risk of psychosis (EDIE-2): A multisite randomised controlled trial of cognitive therapy for at risk mental states. Archives of General Psychiatry, eScholarID:133028

2010

  • Brkus E, Stirling J, French P, Morrison A, Bentall R, Lewis S. (2010). Distress and metacognition in psychosis prone individuals: Comparing high schizotypy to the at-risk mental state. Journal of Nervous and Mental Diease, 198(2), 99-104. eScholarID:133031 | DOI:10.1097/NMD.0b013e3181cc418a

2007

  • Drake R, Dunn G, Tarrier N, Bentall RP, Haddock G, Lewis SW. (2007). Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. Journal of Clinical Psychiatry, 68 (1), 81-86. eScholarID:1d13809

2006

  • Haddock G, Lewis SW, Bentall RP, Dunn G, Drake R, Tarrier N. (2006). Influence of age on outcome of psychological treatments in first-episode psychosis. Br J Psychiatry, 188, eScholarID:1d13774 | DOI:10.1192/bjp.188.3.250
  • Jones P, Barnes T, Davies LM, Dunn G, Lloyd H, Hayhurst K, Murray R, Markwick A, Lewis SW. (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 63( 10), 1079-87. eScholarID:1d14103 | DOI:10.1001/archpsyc.63.10.1079
  • Lewis SW, Barnes TR, Davies LM, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB. (2006). Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia. Schizophr Bull, 32 (4), 715-23. eScholarID:1d13151 | DOI:10.1093/schbul/sbj067
  • Lewis, SW, Davies, LM, Jones, P, Barnes, T, Murray, R, Kerwin, R, Taylor, DD.M., Hayhurst, KP, Markwick, A, Lloyd, H, Dunn, G. (2006). Randomised controlled trials of conventional antipsychotics versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment, 10(17), eScholarID:1d12623
  • Tarrier N, Haddock G, Lewis SW, Drake R, Gregg L. (2006). Suicide behaviour over 18 months in recent onset schizophrenic patients: the effects of CBT. Schizophr Res, 83( 1), eScholarID:1d13776 | DOI:10.1016/j.schres.2005.12.846

2005

  • Lewis SW, Tarrier N, Tarrier N, Drake R. (2005). Integrating non-drug treatments in early schizophrenia. British Journal Of Psychiatry, 48 Supplement, eScholarID:1d26861

2004

  • Tarrier, N, Lewis, SW, Haddock, G, Bentall, R, Drake, R, Kinderman, P, Kingdon, D, Siddle, R, Everitt, J, Leadley, K, Benn, A, Grazebrook, K, Haley, C, Akhtar, S, Davies, L, Palmer, S, Dunn, G. (2004). Cognitive-behavioural therapy in first-episode and early schizophrenia - 18-month follow-up of a randomised controlled trial. British Journal Of Psychiatry, 184, 231-239. eScholarID:1d26170 | DOI:10.1192/bjp.184.3.231

2003

  • Drake R, Lewis SW. (2003). Insight and neurocognition in schizophrenia. Schizophrenia Research, 62(1-2), 165-173. eScholarID:1d25407 | DOI:10.1016/S0920-9964(02)00382-1
  • Gabrobvska-Johnson VS, Scott M, Jeffries S, Thaker N, Baldwin RC, Burns AS, Lewis SW, Deakin JFW. (2003). Right-hemisphere encephalopathy in elderly subjects with schizophrenia evidence from neuropsychological and brain imaging studies. Psychopharmacology (Berl), 169 (3-4), 367-375. eScholarID:1d6408 | DOI:10.1007/s00213-003-1524-9
  • Haley CJ, Drake R, Benatall RP, Lewis SW. (2003). Health beliefs link to duration of untreated psychosis and attitudes to late treatment in early psychosis. Social Psychiatry and Psychiatric Epidemiology, 38(6), 311-316. eScholarID:1d25406
  • Hayhurst KP, Brown P, Lewis SW. (2003). Postcode prescribing for schizophrenia. British Journal of Psychiatry, 182, 281-283. eScholarID:1d25408
  • Stirling J, White C, Lewis SW, Hopkins RR, Tantam D, Huddy A, Montegue L. (2003). Neurocognitive function and outcome in first0episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophrenia Research, 65 (2-3), 75-86. eScholarID:1d12444 | DOI:10.1016/S0920-9964(03)00014-8
  • Barkus EJ, Stirling J, Lewis SW, Hopkins R. (2003). The profile of schizotypy in a normal (student) population. Schizophrenia Research, 60(1), 10-10. eScholarID:17d175
  • Bentall RP, Lewis SW, Tarrier G, Haddock R, Drake R, Day J. (2003). Relationships matter: the impact of the therapeutic alliance on outcome in schizophrenia. Schizophrenia Research, 60(1), 319-319. eScholarID:17d278
  • Drake RJ, Lewis SW. (2003). More than one dimension of insight in a first episode follow-up study of non-affective psychosis. Schizophrenia Research, 60(1), 168-168. eScholarID:17d906
  • Hayhurst KP, Brown P, Lewis SW. (2003). Postcode prescribing for schizophrenia. Schizophrenia Research, 60(1), 337-337. eScholarID:17d827
  • Hopkins RS, Lewis SW. (2003). Negative priming in first episode psychosis. Schizophrenia Research, 60(1), 139-139. eScholarID:17d226
  • Massie J, Marwick A, Sowden E, Mahmood A, Lewis SW. (2003). Psychopathological influences on self-rated and external assessments of quality of life in schizophrenia. Schizophrenia Research, 60(1), 22-22. eScholarID:17d225
  • Morrison AP, Bentall RP, French P, Kilcommons A, Green J, Walford L, Lewis SW. (2003). Cognitive therapy in ultra high risk individuals for psychosis: randomized controlled trial. Schizophrenia Research, 60(1), 326-326. eScholarID:17d127
  • Stirling J, White C, Lewis SW, Hopkins R, Huddy A, Montague L. (2003). Neurological soft signs (NSSS) in first episode psychosis predict ten year outcome. Schizophrenia Research, 60(1), 158-158. eScholarID:17d569

2002

  • Guthrie EA, Lewis SW. (2002). Modern Psychiatry for Student Doctors. Churchill Livingstone. eScholarID:4d72
  • Lewis SW, Buchanan RW. (2002). Schizophrenia. Oxford University Press. eScholarID:4d92
  • Hughes R, Turner S, Taylor D, Lewis SW. (2002). Delirium. Neurological Emergencies. ( 3, ). eScholarID:3d999
  • Drake R, Lewis SW. (2002). Treatment of first episode and prodromal signs. Psychiatry, 1(10), 56-59. eScholarID:1d25410
  • Guaerra A, Fearon P, Sham P, Jones P, Lewis SW, Mata I, Murray R. (2002). The relationship between predisposing factors, premorbid function and symptom dimensions in psychosis: an integrated approach. European Psychiatry: the Journal of the Association of European Psychiatrists, 17(6), 311-320. eScholarID:1d25404
  • Hayhurst K, Brown P, Lewis SW. (2002). The costs of clozapine: a controlled, mirror-image study. Journal of Psychopharmacology, 16, 169-176. eScholarID:1d25402
  • Hayhurst KP, Brown P, Lewis SW. (2002). The effectiveness of clozapine: a controlled, population-based, mirror-image study. Schizophrenia Research, 53(3), 227-227. eScholarID:1d25412
  • Lewis SW. (2002). The European First-Episode Schizophrenia Network. British Journal of Psychiatry, 43, s1-2. eScholarID:1d25405
  • Lewis, SW, Tarrier, N, Haddock, G, Bentall, RP, Kinderman, P, Kingdon, D, Siddle, R, Drake, R, Everitt, J, Leadley, K, Benn, A, Grazebrook, K, Haley, C, Akhtar, S, Davies, LM, Palmer, S, Faragher, B, Dunn, G. (2002). Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. British Journal Of Psychiatry, 181(S43), s91-s97. eScholarID:1d23693
  • Morrison A, Bentall R, French P, Walford L, Kilcommons A, Lewis SW. (2002). A randomised controlled trial of early detection and cognitive therapy in individuals at risk of psychosis. British Journal of Psychotherapy, 181(43), s91-97. eScholarID:1d25403
  • Morrison A, Bentall R, French P, Walford L, Kilcommons A, Lewis SW. (2002). A randomised controlled trial of early detection and cognitive therapy in individuals of psychosis. Study design and interim analyses. British Journal Of Psychiatry, 181supp 43, 578-584. eScholarID:1d23991
  • Stirling J, White C, Lewis SW, Hopkins R, Huddy A, Montague L. (2002). Onset predictors of clinical and functional outcome in individuals first diagnosed with a schizophrenic disorder 10-12 years ago. Schizophrenia Research, 53(3), 54-54. eScholarID:1d25411
  • Drake R, Lewis SW. (2002). Neurocognitive predictors of poor insight in early schizophrenia. Schizophrenia Research, 53(3), 127-127. eScholarID:17d224
  • Drake R, Tarrier N, Lewis SW. (2002). Predictors of medium-term outcome from first-episode schizophrenia. Schizophrenia Research, 50-50. eScholarID:17d223
  • Haley CJ, Drake R, Benatall R, Lewis SW. (2002). Class of drug treatment does not affect drug attitudes in early schizophrenia. Schizophrenia Research, 53(3), 227-227. eScholarID:17d126
  • Hopkins RS, White CJ, Stirling J, Morris J, Montague L, Lewis SW. (2002). Deaths in a first episode psychosis cohort in the 12 years after onset. Schizophrenia Research, 53(3), 56-56. eScholarID:17d568
  • Morrison A, Bentall R, French P, Kilcommons A, Lewis SW. (2002). Very early intervention in prodromal psychosis: A randomised trial. Schizophrenia Research, 53(3), 46-46. eScholarID:17d172
  • White CJ, Hopkins RS, Stirling J, Morris J, Montague L, Lewis SW. (2002). Non-natural deaths and duration of untreated psychosis (DUP) in a first-episode psychosis cohort. Schizophrenia Research, 53(3), 46-46. eScholarID:17d173

2001

  • Lewis SW, Jagger RG, Treasure E. (2001). The oral health of psychiatric-in-patients in South Wales. Spec care dentist, 21(5), 169-175. eScholarID:1d25401

2000

  • Drake R, Haley C J, Akhtar S, Lewis SW. (2000). Causes and consequences of duration of untreated psychosis in first episode schizophrenia. British Journal Of Psychiatry, 177, 151-155. eScholarID:1d23990

  • Jones PB, Barnes TR, Davies LM, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Marwick A, Lewis SW. Randomized controlled trial of effect on quality of life of second generation versus first generation antipsychotic drugs in schizophrenia - CUtLASS 1. Archives of General Psychiatry, eScholarID:1d33156

Top of page

| Skip to main content | Skip to navigation | Skip to Search |